← Leaderboards
Geoffrey J. Clark
Clinical Sciences
$2,883,684
Attributed
$3,550,735
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $722.5K · FY2007–19$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,550,735 · 7
By mechanism
R01$2,339,458 · 2
P20$848,862 · 4
R21$362,415 · 1
Top collaborators
- Lauretta Rund4 shared
- Lawrence B Schook4 shared
Others in their field
Top investigators on “Tumor Suppressor Proteins”
- Scott W Lowe · Sloan-Kettering Inst Can Research$30,621,807
- Carol Prives · Icahn School Of Medicine At Mount Sinai$25,974,663
- Pier Paolo Pandolfi · Sloan-Kettering Institute For Cancer Res$25,707,040
- Xinbin Chen · Medical College Of Georgia (Mcg)$23,449,975
- Carlo M Croce · Thomas Jefferson University$21,878,300
- Wei Gu · Columbia University Health Sciences$21,628,257
Research focus
Tumor Suppressor ProteinsGuanine Nucleotide Binding ProteinOncogenesMalignant NeoplasmsProteinsApoptosisNeoplastic TransformationSeriesTumorigenicSignal PathwayAnimal ModelInhibitor/AntagonistIn VivoTranscription FactorProtein KinaseTumorOncogene ProteinsNeoplastic CellMediatingMouse ModelFamilyDesignPhenotypePathway Interactions
Grant awards (33)
NOVEL PAN-RALGEF INHIBITORS TO BLOCK PANCREATIC CANCER.$194,940
R21 · FY2019 · CA · contact PI
NOVEL PAN-RALGEF INHIBITORS TO BLOCK PANCREATIC CANCER.$167,475
R21 · FY2018 · CA · contact PI
The role of the Ras effector Nore1a in tumor suppression$263,571
R01 · FY2014 · CA · contact PI
Oncopigs as a better model for human cancer$292,476
R01 · FY2013 · CA · contact PI
The role of the Ras effector Nore1a in tumor suppression$255,419
R01 · FY2013 · CA · contact PI
Oncopigs as a better model for human cancer$309,806
R01 · FY2012 · CA · contact PI
The role of the Ras effector Nore1a in tumor suppression$271,722
R01 · FY2012 · CA · contact PI
The role of the Ras effector Nore1a in tumor suppression$269,911
R01 · FY2011 · CA · contact PI
Oncopigs as a better model for human cancer$196,106
R01 · FY2011 · CA · contact PI
The role of the Ras effector Nore1a in tumor suppression$278,258
R01 · FY2010 · CA · contact PI
COBRE PROJ 7: CONTROL OF TUMOR GROWTH BY RAS-RELATED PROTEINS$242,023
P20 · FY2010 · RR · contact PI
Oncopigs as a better model for human cancer$202,189
R01 · FY2010 · CA · contact PI
COBRE PROJ 7: CONTROL OF TUMOR GROWTH BY RAS-RELATED PROTEINS$117,412
P20 · FY2009 · RR · contact PI
COBRE PROJ 7: CONTROL OF TUMOR GROWTH BY RAS-RELATED PROTEINS$241,375
P20 · FY2008 · RR · contact PI
COBRE PROJ 7: CONTROL OF TUMOR GROWTH BY RAS-RELATED PROTEINS$248,052
P20 · FY2007 · RR · contact PI
The role of Ras-related proteins in transformation$0
Z01 · FY2005 · SC
Mechanisms of effector activation by the RAS oncogene$0
Z01 · FY2005 · SC
The Role of Nore1 Class Effectors in Ras-Mediated Transf$0
Z01 · FY2005 · SC
The Role of Novel Class Effectors in Ras Mediated Transf$0
Z01 · FY2004 · SC
The role of Ras-related proteins in transformation$0
Z01 · FY2004 · SC
Mechanisms of effector activation by the RAS oncogene$0
Z01 · FY2004 · SC
Mechanisms of effector activation by the RAS oncogene$0
Z01 · FY2003 · SC
Nore1 Class Effectors in Ras Mediated Transformation$0
Z01 · FY2003 · SC
Role of Ras-related proteins in transformation$0
Z01 · FY2003 · SC
The role of Ras-related proteins in transformation$0
Z01 · FY2002 · SC
The Role of Nore1 Class Effectors in Ras Mediated Transf$0
Z01 · FY2002 · SC
Mechanisms of effector activation by the RAS oncogene$0
Z01 · FY2002 · SC
The role of Ras-related proteins in transformation$0
Z01 · FY2001 · SC
Nore1 Class Effectors in Ras Mediated Transformation$0
Z01 · FY2001 · SC
Mechanisms of effector activation by the RAS oncogene$0
Z01 · FY2001 · SC
The role of Ras-related proteins in transformation$0
Z01 · FY2000 · SC
NOREL CLASS EFFECTORS IN RAS MEDIATED TRANSFORMATION$0
Z01 · FY2000 · SC
Mechanisms of effector activation by the RAS oncogene$0
Z01 · FY2000 · SC